Organ‐on‐chip for advancing CAR therapy
Abstract Despite great strides of progress, at least 60% of the responding patients relapse to CAR therapy across the blood malignancies. Off‐tumor toxicity apart from functional deficits, cytopenia and infection are the major unfavourable effect of CAR therapy. Models, which faithfully recapitulate...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Clinical & Translational Immunology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cti2.70024 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850078436391911424 |
|---|---|
| author | Lightson Ngashangva Sunil Martin |
| author_facet | Lightson Ngashangva Sunil Martin |
| author_sort | Lightson Ngashangva |
| collection | DOAJ |
| description | Abstract Despite great strides of progress, at least 60% of the responding patients relapse to CAR therapy across the blood malignancies. Off‐tumor toxicity apart from functional deficits, cytopenia and infection are the major unfavourable effect of CAR therapy. Models, which faithfully recapitulate the physiology and complexities of immunocompetent tumor microenvironment (TME), paused challenges in capturing potential off‐tumor effects of CAR therapy. Importantly, a landmark change in the legislation allows US Food and Drug Administration and New Drugs and Clinical Trial Rules in India encourages researchers to replace animal testing with cell culture approaches relevant to human system. Organ‐on‐chip (OOC) based on microfluidics technology can potentially emulate multiple biochemical and biophysical intricacies of blood and lymph flow at microscale. Nonetheless, how the evolving microfluidics technology can be enabling to real‐time testing of cell and gene is yet to be realised. |
| format | Article |
| id | doaj-art-686ce29243d84d3ebda4ad0dab6611d6 |
| institution | DOAJ |
| issn | 2050-0068 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical & Translational Immunology |
| spelling | doaj-art-686ce29243d84d3ebda4ad0dab6611d62025-08-20T02:45:33ZengWileyClinical & Translational Immunology2050-00682025-01-01142n/an/a10.1002/cti2.70024Organ‐on‐chip for advancing CAR therapyLightson Ngashangva0Sunil Martin1Biosensors and Biomicrofluidics Laboratory, Transdisciplinary Biology Program Rajiv Gandhi Centre for Biotechnology (RGCB) Thiruvananthapuram Kerala IndiaSynthetic Immunology Laboratory, Division of Cancer Research Rajiv Gandhi Centre for Biotechnology (RGCB) Thiruvananthapuram Kerala IndiaAbstract Despite great strides of progress, at least 60% of the responding patients relapse to CAR therapy across the blood malignancies. Off‐tumor toxicity apart from functional deficits, cytopenia and infection are the major unfavourable effect of CAR therapy. Models, which faithfully recapitulate the physiology and complexities of immunocompetent tumor microenvironment (TME), paused challenges in capturing potential off‐tumor effects of CAR therapy. Importantly, a landmark change in the legislation allows US Food and Drug Administration and New Drugs and Clinical Trial Rules in India encourages researchers to replace animal testing with cell culture approaches relevant to human system. Organ‐on‐chip (OOC) based on microfluidics technology can potentially emulate multiple biochemical and biophysical intricacies of blood and lymph flow at microscale. Nonetheless, how the evolving microfluidics technology can be enabling to real‐time testing of cell and gene is yet to be realised.https://doi.org/10.1002/cti2.70024CAR therapymicrofluidicsorgan‐on‐chiptumor immune microenvironment |
| spellingShingle | Lightson Ngashangva Sunil Martin Organ‐on‐chip for advancing CAR therapy Clinical & Translational Immunology CAR therapy microfluidics organ‐on‐chip tumor immune microenvironment |
| title | Organ‐on‐chip for advancing CAR therapy |
| title_full | Organ‐on‐chip for advancing CAR therapy |
| title_fullStr | Organ‐on‐chip for advancing CAR therapy |
| title_full_unstemmed | Organ‐on‐chip for advancing CAR therapy |
| title_short | Organ‐on‐chip for advancing CAR therapy |
| title_sort | organ on chip for advancing car therapy |
| topic | CAR therapy microfluidics organ‐on‐chip tumor immune microenvironment |
| url | https://doi.org/10.1002/cti2.70024 |
| work_keys_str_mv | AT lightsonngashangva organonchipforadvancingcartherapy AT sunilmartin organonchipforadvancingcartherapy |